H5N1 influenza virus vaccine intranasal - Ology Bioservices

Drug Profile

H5N1 influenza virus vaccine intranasal - Ology Bioservices

Alternative Names: GelVac™ nasal influenza vaccine

Latest Information Update: 05 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator DelSite Biotechnologies
  • Developer Ology Bioservices
  • Class Influenza A virus H5N1 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Influenza virus infections

Most Recent Events

  • 02 Oct 2017 Nanotherapeutics is now called as Ology Bioservices
  • 20 Apr 2016 This programme is still active
  • 03 Oct 2011 Interim adverse events and immunogenicity data from a phase I trial in Influenza virus infection released by Nanotherapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top